20 abstracts on Dupixent® and Itepekimab for COPD and asthma treatment to be presented at ERS Congress 2024.
20 abstracts on Dupixent® (dupilumab) and investigational therapy Itepekimab will be presented at ERS Congress 2024, showcasing potential for treating respiratory diseases like COPD and asthma. Regeneron and Sanofi will present data on Dupixent's exacerbation reduction and lung function improvement in COPD. Other presentations include novel asthma imaging studies and Itepekimab data in former smokers with COPD, highlighting targeting key inflammation drivers to improve patient outcomes.
August 26, 2024
9 Articles